<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Summary >
<Summary id="CDR0000062794" LegacyPDQID=""><SummaryMetaData><SummaryType>Treatment</SummaryType><SummaryAudience>Health professionals</SummaryAudience><SummaryLanguage>English</SummaryLanguage><SummaryDescription>Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors).</SummaryDescription><SummaryURL xref="http://cancer.gov/types/pancreatic/hp/pnet-treatment-pdq">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment</SummaryURL><MainTopics><TermRef ref="CDR0000043353">islet cell carcinoma</TermRef></MainTopics></SummaryMetaData><SummaryTitle>Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)</SummaryTitle><AltTitle TitleType="Navlabel">Pancreatic Neuroendocrine Tumors Treatment</AltTitle><AltTitle TitleType="Short">Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)  Treatment</AltTitle><SummarySection id="_1"><SectMetaData><SpecificDiagnosis ref="CDR0000043353">islet cell carcinoma</SpecificDiagnosis><SectionType>Prognosis--legacy</SectionType></SectMetaData><Title>General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</Title><SummarySection id="_263"><Title>Incidence and Mortality</Title><Para id="_264">They are uncommon cancers with about 1,000 new cases
per year in the United States.<Reference refidx="1"/> They account for 3% to 5% of pancreatic malignancies and overall have a better prognosis than the more common pancreatic exocrine tumors.<Reference refidx="1"/><Reference refidx="2"/>  Five-year survival is about 55% when the tumors are localized and resected but only about 15% when the tumors are not resectable.<Reference refidx="2"/>  Overall 5-year survival rate is about 42%.<Reference refidx="1"/></Para><MediaLink ref="CDR0000716331" type="image/jpeg" alt="Graph shows relative survival rate (%) at 0−120 months after diagnosis of endocrine and exocrine cancer of the pancreas." language="en" thumb="Yes" id="_261"><Caption language="en">Figure 1.  Cancer of the Pancreas: Relative Survival Rates (%) by Histologic Subtype, Ages 20+, 12 SEER Areas, 1988-2001. Key, C. Ch 7: Cancer of the pancreas. In: Ries LAG, Young JL, Keel GE, et al. (eds). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.</Caption></MediaLink></SummarySection><SummarySection id="_265"><Title>Pathogenesis</Title><Para id="_2">Tumors of the endocrine pancreas are a collection of tumor cell types collectively referred to as pancreatic neuroendocrine tumors (NETs).  These tumors originate in islet cells.  Although they may be similar or identical in histologic appearance to carcinoid tumors of the gastrointestinal tract, differences in their underlying biology and likely differences in response to therapeutic agents suggest that they should be treated and investigated as a distinct entity.<Reference refidx="3"/>    </Para><Para id="_150">Most pancreatic NETs are sporadic, but some occur as part of the autosomal dominant multiple endocrine neoplasia type-1 (MEN-1) inherited syndrome consisting of tumors of the anterior pituitary, parathyroid, and endocrine pancreas glands, which results from the inactivation of the tumor suppressor gene <GeneName>Menin</GeneName> located on chromosome 11q13.<Reference refidx="4"/> When part of the MEN-1 syndrome, there may be multiple pancreatic tumors.</Para><Para id="_151">Islet tumors may
either be functional (produce one or more active hormones) or nonfunctional.<Reference refidx="4"/> The functional tumors, which usually present with symptoms of hormone hypersecretion, include: </Para><ItemizedList id="_152" Style="bullet"><ListItem>Gastrinoma.</ListItem><ListItem>Insulinoma.</ListItem><ListItem>Glucagonoma.</ListItem><ListItem>Somatostatinoma.</ListItem><ListItem>VIPoma.</ListItem></ItemizedList></SummarySection><SummarySection id="_266"><Title>Prognostic Factors</Title><Para id="_153">Most islet cell cancers are functional, but about 15% are nonfunctional, with presentations similar to the far more common exocrine adenocarcinomas of the pancreas.<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/> Because of the presence of several cell types in the pancreatic islets (alpha, beta, delta, A, B, C, D, E, F), the term, islet cell tumors, refers to at
least five distinct cancers  that, when functional, produce unique metabolic
and clinical characteristics.  The clinical manifestations in functional
tumors may result from the distinctive metabolic effects of the polypeptide(s) secreted by the
cancer cells rather than from tumor bulk or metastatic disease. 
Functional tumors may even be too small  to be detected by conventional
imaging techniques.
</Para><Para id="_258">Nonfunctional tumors tend to present at later clinical stages with symptoms attributable to mass effect or metastases.<Reference refidx="4"/> Although nonfunctional tumors do not produce specific clinical syndromes, they may secrete inactive amine and peptide products such as the following: </Para><ItemizedList id="_222" Style="bullet"><ListItem>Neurotensin.</ListItem><ListItem>Alpha-subunit of human chorionic gonadotropin (alpha-hCG).</ListItem><ListItem>Neuron-specific enolase.</ListItem><ListItem>Pancreatic polypeptide.</ListItem><ListItem>Chromogranin A.</ListItem></ItemizedList></SummarySection><SummarySection id="_267"><Title>Diagnostics</Title><Para id="_3">The frequent long delays between initial symptoms and diagnosis and the varied
effects of the polypeptides secreted often necessitate involvement of multiple
surgical and medical subspecialties.  Surgery is the only curative
modality.  Surgery is often used even in the setting of metastatic disease to alleviate the symptoms of hormonal hypersecretion.<Reference refidx="4"/> Effective
palliation may be achieved because of the slow-growing nature of the majority
of these tumors and the potential use of antihormonal pharmacologic therapy
(e.g., cimetidine in the ulcer-producing Zollinger-Ellison syndrome). 
  In patients with indolent, slow-growing
metastatic islet cell tumors, the best therapy may be careful observation,
and no treatment until palliation is required.  In patients with MEN-1 in which
85% have pancreatic islet cell tumors, 90% have hyperparathyroidism, and 65%
have pituitary tumors, and they are less likely to be cured by pancreatic resection than
are patients with sporadic islet cell tumors.  With the exception of pain
relief from bone metastases, radiation therapy has a limited role in this
disease.
</Para><Para id="_155">Tumor localization and staging studies include imaging with computed tomography (CT) with or without magnetic resonance imaging (MRI), and endoscopic ultrasound.  In addition, somatostatin-receptor scintigraphy and single-photon emission CT may be useful adjuncts.  However, somatostatin-receptor scintigraphy has diminished utility in localizing insulinomas versus other pancreatic NETs, since insulinomas often have a low density of somatostatin receptors.<Reference refidx="4"/>  If the noninvasive tests do not reveal a tumor, but clinical suspicion remains high, more invasive and technically demanding tests, such as selective arteriography or selective arterial stimulation (with a secretagogue specific for the suspected tumor type), may be useful.<Reference refidx="7"/></Para><Para id="_243">Some of the tumor types have unique characteristics that require specific approaches in their diagnosis and initial evaluation.</Para><SummarySection id="_244"><Title>Gastrinoma</Title><Para id="_245">Diagnosis is dependent on elevated serum gastrin and elevated gastric acid
levels.  Provocative testing with calcium and secretin shows considerable
overlap, and the value of these tests is limited.  Zollinger-Ellison syndrome
(ZES) is a syndrome of unrelenting peptic ulcer disease, diarrhea, and gastric
hyperacidity, associated with a gastrin-producing tumor. (Refer to the <SummaryRef href="CDR0000062736#_119" url="/about-cancer/treatment/side-effects/constipation/GI-complications-hp-pdq">Diarrhea</SummaryRef>   section in the PDQ summary on <SummaryRef href="CDR0000062736" url="/about-cancer/treatment/side-effects/constipation/GI-complications-hp-pdq">Gastrointestinal Complications</SummaryRef> for more information.)  It accounts for less
than 1% of all peptic ulcer disease. About 15% to 35% of gastrinomas are associated with the MEN-1 syndrome and up to 50% are malignant.  Up to 33% of gastrinomas have liver metastases.<Reference refidx="4"/></Para><OrderedList id="_246" Style="Arabic"><ListTitle>Diagnostic tests:
</ListTitle><ListItem>BAO:MAO ≥ = 0.6 (Basal Acid Output:Maximal Acid Output).
</ListItem><ListItem>Overnight AO ≥ = 100 mmol.</ListItem><ListItem>BAO ≥ = 10 mmol/hr.</ListItem><ListItem> Serum gastrin 10 times normal or &gt;500 pg/mL (the
accuracy of gastrin assays may vary widely).
</ListItem><ListItem>Secretin test: 1 unit/kg IV rapid injection:  Positive = 100% increase
in gastrin within 10 minutes; 2 units/kg:  Positive = 100% increase
over baseline.
</ListItem><ListItem>Elevated human chorionic gonadotropin levels.</ListItem></OrderedList></SummarySection><SummarySection id="_247"><Title>Insulinoma</Title><Para id="_248">Insulinomas are far more likely to be benign than malignant.  Only 10% are
multiple, and only 10% are malignant. About 5% to 8% are associated with MEN-1 syndrome.<Reference refidx="4"/>  The
clinical manifestations are those of hypoglycemia, which results from
inappropriate secretion of insulin by the tumor.    Fasting hypoglycemia (&lt;40 mg/dL) associated with
an elevated insulin level (in the absence of exogenous administration of
insulin) is pathognomonic.  Measurement of plasma proinsulin may be helpful for
diagnosing insulin-secreting carcinomas.  These tumors are usually slow-growing tumors
and, when localized to the pancreas or regional lymph nodes, can be cured with
pancreatic resection.</Para><Para id="_249">The approach to management depends on carefully
performed preoperative localization studies and the findings at exploratory
laparotomy. In a retrospective case series of 30 patients with 32 pancreatic insulinomas, the combination of preoperative dual-phase thin-section multidetector CT and endoscopic sonography correctly identified and localized all of the tumors.<Reference refidx="8"/>  These tests, with or without MRI, have replaced older, more invasive, and technically challenging tests, such as percutaneous transhepatic portal venous sampling and arterial stimulation with venous sampling except for unusual circumstances in which the imaging tests are unsuccessful.<Reference refidx="4"/><Reference refidx="9"/></Para></SummarySection><SummarySection id="_250"><Title>Glucagonoma</Title><Para id="_251">Glucagonoma is the third most common endocrine-secreting islet cell tumor. About 75% of glucagonomas are malignant.<Reference refidx="4"/>  Necrolytic migratory erythema, hyperglycemia,
and venous thrombosis comprise a virtually diagnostic triad.  A serum glucagon level greater than 1000 pg/mL confirms the diagnosis. These tumors tend to be large and easily visible on CT scan.  Somatostatin receptor scintigraphy scanning may be a useful adjunct in detecting metastases.</Para></SummarySection><SummarySection id="_252"><Title>Miscellaneous islet cell tumors</Title><Para id="_253">These tumors are rare but have defined clinical syndromes associated with specific production of polypeptide hormone production by islet cell tumors. Because of their rarity and similar approaches to management, they are grouped in the section on treatment.  Miscellaneous tumors include the following: </Para><ItemizedList id="_254" Style="bullet"><ListItem>VIPoma (Verner-Morrison Syndrome) is characterized by watery diarrhea,
hypokalemia, and achlorhydria.<Para id="_255">A serum vasoactive intestinal peptide (VIP)  greater than 200 pg/mL is diagnostic.<Reference refidx="4"/> These tumors can generally be easily localized by CT scan.  Somatostatin receptor scintigraphy scanning may be a useful adjunct in detecting metastases.</Para></ListItem><ListItem>Somatostatinoma.
<Para id="_256">These tumors are particularly rare.  They often present with diarrhea, steatorrhea, diabetes, and/or gallstones.  Decreased pancreatic secretion of enzymes and bicarbonate accounts for the diarrhea and steatorrhea.  Somatostatin-mediated inhibition of cholecystokinin leads to gallstone formation. Somatostatin also inhibits insulin, producing hyperglycemia. The diagnosis is made by a fasting serum somatostatin level greater than 100 pg/mL.  CT scan, MRI, and endoscopic ultrasound can usually help localize and stage the tumor.  Most of these tumors are malignant and have metastases at diagnosis.</Para></ListItem></ItemizedList></SummarySection></SummarySection><SummarySection id="_225"><Title>Related Summaries</Title><ItemizedList id="_226" Style="bullet">
     <ListItem><SummaryRef href="CDR0000062893" url="/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq">Gastrointestinal Carcinoid Tumors Treatment</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062890" url="/types/thyroid/hp/medullary-thyroid-genetics-pdq">Genetics of Endocrine and Neuroendocrine Neoplasias</SummaryRef></ListItem><ListItem><SummaryRef href="CDR0000062951" url="/types/pancreatic/hp/pancreatic-treatment-pdq">Pancreatic Cancer Treatment</SummaryRef></ListItem></ItemizedList></SummarySection><ReferenceSection><Citation idx="1">Ries LAG, Young JL, Keel GE, et al., eds.: SEER Survival Monograph: Cancer Survival Among Adults: U. S. SEER Program, 1988-2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute, 2007. NIH Pub. No. 07-6215.</Citation><Citation idx="2">Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</Citation><Citation idx="3" PMID="21263089">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011.</Citation><Citation idx="4" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation><Citation idx="5" PMID="12039924">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002.</Citation><Citation idx="6" PMID="17967523">O'Grady HL, Conlon KC: Pancreatic neuroendocrine tumours. Eur J Surg Oncol 34 (3): 324-32, 2008.</Citation><Citation idx="7" PMID="8013189">King CM, Reznek RH, Dacie JE, et al.: Imaging islet cell tumours. Clin Radiol 49 (5): 295-303, 1994.</Citation><Citation idx="8" PMID="14500214">Gouya H, Vignaux O, Augui J, et al.: CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181 (4): 987-92, 2003.</Citation><Citation idx="9" PMID="18156937">Nikfarjam M, Warshaw AL, Axelrod L, et al.: Improved contemporary surgical management of insulinomas: a 25-year experience at the Massachusetts General Hospital. Ann Surg 247 (1): 165-72, 2008.</Citation></ReferenceSection></SummarySection><SummarySection id="_4"><SectMetaData><SpecificDiagnosis ref="CDR0000043353">islet cell carcinoma</SpecificDiagnosis><SectionType>Cellular classification--legacy</SectionType></SectMetaData><Title>Cellular Classification of Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</Title><Table id="_80"><Title>Table 1.  Endocrine Tumors of the Pancreas</Title><TGroup Cols="3"><ColSpec ColName="col1" ColNum="1" ColWidth="33.33%"/><ColSpec ColName="col2" ColNum="2" ColWidth="33.33%"/><ColSpec ColName="col3" ColNum="3" ColWidth="33.33%"/><THead><Row><entry Align="Center">Islet Cells</entry><entry Align="Center">Secreted Active Agent</entry><entry Align="Center">Tumor and Syndrome</entry></Row></THead><TFoot><Row><entry NameEnd="col3" NameSt="col1">ACTH = adrenocorticotropin; MSH = melanocyte-stimulating hormone; VIP = vasoactive intestinal peptide; WDHA = watery diarrhea, hypokalemia, and achlorhydria; 5-HT = serotonin.</entry></Row></TFoot><TBody><Row><entry>Alpha</entry><entry>Glucagon</entry><entry>Glucagonoma (diabetes,
                                               dermatitis)</entry></Row><Row><entry>Beta</entry><entry>Insulin</entry><entry>Insulinoma (hypoglycemia)</entry></Row><Row><entry>Delta</entry><entry>Somatostatin</entry><entry>Somatostatinoma (mild diabetes); diarrhea/steatorrhea; gallstones</entry></Row><Row><entry>D </entry><entry>Gastrin </entry><entry>Gastrinoma (peptic ulcer disease)</entry></Row><Row><entry MoreRows="5">A -&gt; D</entry><entry>VIP and/or  other undefined  mediators</entry><entry MoreRows="2">WDHA</entry></Row><Row><entry>5-HT </entry></Row><Row><entry>ACTH </entry></Row><Row><entry MoreRows="2">MSH</entry><entry>Carcinoid</entry></Row><Row><entry>Cushing syndrome</entry></Row><Row><entry>Hyperpigmentation</entry></Row><Row><entry Align="Center"><Strong>Interacinar Cells</Strong></entry><entry Align="Center"><Strong>Secreted Active Agent</Strong></entry><entry Align="Center"><Strong>Tumor and Syndrome</Strong></entry></Row><Row><entry>F</entry><entry>Pancreatic polypeptide</entry><entry>Multiple hormonal syndromes</entry></Row><Row><entry>EC  </entry><entry>5-HT </entry><entry>Carcinoid</entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_199"><SectMetaData><SpecificDiagnosis ref="CDR0000043353">islet cell carcinoma</SpecificDiagnosis><SectionType>Stage explanation--legacy</SectionType></SectMetaData><Title>Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</Title><Para id="_200">Note:  The American Joint Committee on Cancer has  published the 7th edition of the <Emphasis>AJCC Cancer Staging Manual</Emphasis>, which for the first time incorporates pancreatic neuroendocrine tumors in the same staging system as pancreatic exocrine tumors.<Reference refidx="1"/> The classification of these tumors as benign versus malignant is not always consistent, so the AJCC recommends that all pancreatic neuroendocrine tumors be staged using this system and reported to cancer registries.  It also recommends that the protocol developed by the College of American Pathologists for endocrine pancreatic tumors be used to examine and stage specimens.<Reference refidx="2"/></Para><SummarySection id="_201"><Title>Definitions of TNM</Title><Para id="_259">The American Joint Committee on Cancer has designated staging by TNM
classification to define pancreatic neuroendocrine tumors (islet cell tumors).<Reference refidx="1"/></Para><Table id="_123"><Title>Table 2.  Primary Tumor (T)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="9.41%"/><ColSpec ColName="col2" ColNum="2" ColWidth="90.58%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>b</Superscript>This also includes the "PanInIII" classification.</entry></Row></TFoot><TBody><Row><entry>TX</entry><entry>Primary tumor cannot be assessed.</entry></Row><Row><entry>T0</entry><entry>No evidence of primary tumor.</entry></Row><Row><entry>Tis</entry><entry>Carcinoma <Emphasis>in situ</Emphasis>.<Superscript>b</Superscript></entry></Row><Row><entry>T1</entry><entry>Tumor limited to the pancreas, ≤2 cm in greatest dimension.</entry></Row><Row><entry>T2</entry><entry>Tumor limited to the pancreas, &gt;2 cm in greatest dimension.</entry></Row><Row><entry>T3</entry><entry>Tumor extends beyond the pancreas but without involvement of the celiac axis or the superior mesenteric artery.</entry></Row><Row><entry>T4</entry><entry>Tumor involves the celiac axis or the superior mesenteric artery (unresectable primary tumor).</entry></Row></TBody></TGroup></Table><Table id="_124"><Title>Table 3.  Regional Lymph Nodes (N)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="9.21%"/><ColSpec ColName="col2" ColNum="2" ColWidth="90.78%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</entry></Row></TFoot><TBody><Row><entry>NX</entry><entry>Regional lymph nodes cannot be assessed.</entry></Row><Row><entry>N0</entry><entry>No regional lymph node metastasis.</entry></Row><Row><entry>N1</entry><entry>Regional lymph node metastasis.</entry></Row></TBody></TGroup></Table><Table id="_125"><Title>Table 4.  Distant Metastasis (M)<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="8.69%"/><ColSpec ColName="col2" ColNum="2" ColWidth="91.30%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</entry></Row></TFoot><TBody><Row><entry>M0</entry><entry>No distant metastasis.</entry></Row><Row><entry>M1</entry><entry>Distant metastasis.</entry></Row></TBody></TGroup></Table><Table id="_126"><Title>Table 5.  Anatomic Stage/Prognostic Groups<Superscript>a</Superscript></Title><TGroup Cols="4"><ColSpec ColName="col1" ColNum="1" ColWidth="25.00%"/><ColSpec ColName="col2" ColNum="2" ColWidth="25.00%"/><ColSpec ColName="col3" ColNum="3" ColWidth="25.00%"/><ColSpec ColName="col4" ColNum="4" ColWidth="25.00%"/><THead><Row><entry Align="Center">Stage</entry><entry Align="Center">T</entry><entry Align="Center">N</entry><entry Align="Center">M</entry></Row></THead><TFoot><Row><entry NameEnd="col4" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</entry></Row></TFoot><TBody><Row><entry>0</entry><entry>Tis</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IA</entry><entry>T1</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IB</entry><entry>T2</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry>IIA</entry><entry>T3</entry><entry>N0</entry><entry>M0</entry></Row><Row><entry MoreRows="2">IIB</entry><entry>T1</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T2</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>T3</entry><entry>N1</entry><entry>M0</entry></Row><Row><entry>III</entry><entry>T4</entry><entry>Any N</entry><entry>M0</entry></Row><Row><entry> IV</entry><entry>Any T</entry><entry>Any N</entry><entry>M1</entry></Row></TBody></TGroup></Table><Para id="_203"><Strong>Histologic Grade (G)<Superscript>a</Superscript></Strong></Para><Para id="_204">A two-, three-, or four-grade system may be used.  If a grading system is not specified, generally the following system is used:</Para><Table id="_205"><Title>Table 6.  Histologic Grading  System<Superscript>a</Superscript></Title><TGroup Cols="2"><ColSpec ColName="col1" ColNum="1" ColWidth="11.57%"/><ColSpec ColName="col2" ColNum="2" ColWidth="88.42%"/><TFoot><Row><entry NameEnd="col2" NameSt="col1">G = grade</entry></Row><Row><entry NameEnd="col2" NameSt="col1"><Superscript>a</Superscript>Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</entry></Row></TFoot><TBody><Row><entry>GX</entry><entry>Grade cannot be assessed.</entry></Row><Row><entry>G1</entry><entry>Well differentiated.</entry></Row><Row><entry>G2</entry><entry>Moderately differentiated.</entry></Row><Row><entry>G3</entry><entry>Poorly differentiated.</entry></Row><Row><entry>G4</entry><entry>Undifferentiated.</entry></Row></TBody></TGroup></Table></SummarySection><SummarySection id="_TrialSearch_199_sid_3"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_199_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43353&amp;tt=1&amp;format=2&amp;cn=1">islet cell carcinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_199_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1">Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010, pp 241-9.</Citation><Citation idx="2">Washington K, Tang LH, Berlin J, et al.: Protocol for the examination of specimens from patients with carcinoma of the endocrine pancreas. Northfield, Il: College of American Pathologists, 2011. <ExternalRef xref="http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2012/PancreasExo_12protocol_3200.pdf">Available online</ExternalRef>. Last accessed October 21, 2013.</Citation></ReferenceSection></SummarySection><SummarySection id="_162"><SectMetaData><SpecificDiagnosis ref="CDR0000043353">islet cell carcinoma</SpecificDiagnosis><SectionType>Treatment option overview--legacy</SectionType></SectMetaData><Title>Treatment Option Overview</Title><SummarySection id="_227"><Title>Localized Disease</Title><Para id="_228">If technically and medically feasible, primary management of endocrine tumors of the pancreas involves surgical resection with curative intent.  Given the rare nature of these tumors, surgical approaches are based upon case series and expert opinion rather than randomized controlled trials.<Reference refidx="1"/> The surgical options listed below are based on retrospective series from single reporting centers.<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>[<LOERef href="CDR0000716085">Level of evidence: 3iiD</LOERef> or <LOERef href="CDR0000593395">3iiiD</LOERef>] </Para><Para id="_229">Adjuvant therapy has no proven benefit and is, therefore, investigational.  There have been no well-controlled trials of adjuvant therapy after complete tumor resection.<Reference refidx="5"/></Para></SummarySection><SummarySection id="_230"><Title>Surgical Cytoreduction for Metastases</Title><Para id="_231">Surgery plays a role even in the setting of metastatic disease.  The symptoms of metastatic functional pancreatic neuroendocrine tumors (NETs) may be ameliorated by the reduction of overall tumor burden through surgical debulking.</Para><Para id="_257">The liver is a common site of metastasis from pancreatic NETs.  Because of the slow growth rate of many NETs, liver metastases are often resected when technically feasible.  Resection of all grossly visible liver metastases can be associated with long-term survival and, in the case of symptomatic hormonally functional tumors, symptom relief.<Reference refidx="6"/> Most symptoms from functional tumors respond to this form of surgical debulking.  How much of the favorable survival rates is attributable to patient selection factors is not known (e.g., underlying patient condition, extent of metastases, slow doubling time, and so forth).  </Para><Para id="_260">A variety of alternative approaches to the management of liver metastases have been reported, including gel-foam embolization or transarterial chemoembolization,<Reference refidx="7"/> radioembolization with radioactive microspheres,<Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/> radiofrequency ablation, cryoablation, and percutaneous alcohol ablation. These alternative approaches have been reviewed.<Reference refidx="11"/></Para><Para id="_232"> Results from surgical resection series appear to be more favorable than with these techniques, and surgery is considered to be the standard approach to resectable liver metastases.  However, there are no high-quality studies comparing the various approaches.  A systematic review of evidence comparing liver resection versus other treatments for patients with resectable liver neuroendocrine metastases found no randomized trials, or even quasi-experimental, cohort, or case-control studies in which the patient population given the alternative therapies was similar enough to the surgery group to draw reliable conclusions.<Reference refidx="12"/>  The evidence for resection of all grossly visible liver metastases derives solely from case series.[<LOERef href="CDR0000716085">Level of evidence: 3iiD</LOERef> or <LOERef href="CDR0000593395">3iiiD</LOERef>]</Para><Para id="_234">In most cases, liver metastases are not completely resectable.  Cytoreductive surgery, with or without radiofrequency ablation or cryoablation, has been used to palliate symptoms.  A systematic review found no randomized or quasi-randomized trials comparing cytoreductive surgery to other palliative approaches such as chemotherapy or tumor product inhibitors.<Reference refidx="13"/> The evidence for surgical cytoreduction of unresectable liver metastases is restricted to case series [<LOERef href="CDR0000716085">Level of evidence: 3iiD</LOERef> or <LOERef href="CDR0000593395">3iiiD</LOERef>], and interpretation of outcomes may be strongly affected by patient selection factors.</Para></SummarySection><SummarySection id="_235"><Title>Systemic Therapy for Advanced and Metastatic Disease</Title><Para id="_173">Somatostatin analogs may be effective in reducing the symptoms of functional tumors.<Reference refidx="14"/></Para><Para id="_174">Chemotherapy using drugs such as the following, either alone or in combination, has been shown to have antitumor effects, but evidence is weak or conflicting regarding the impact of chemotherapy on overall survival:<Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/></Para><ItemizedList id="_236" Style="bullet">
     <ListItem>Streptozocin.</ListItem><ListItem>Doxorubicin.</ListItem><ListItem>5-fluorouracil.</ListItem><ListItem>Chlorozotocin.</ListItem><ListItem>Dacarbazine.</ListItem><ListItem>Temozolomide.</ListItem></ItemizedList><Para id="_237">   More recently, a variety of systemic agents have shown biologic or palliative activity, including:<Reference refidx="5"/><Reference refidx="18"/></Para><ItemizedList id="_238" Style="bullet">
     <ListItem>Tyrosine kinase inhibitors (e.g., sunitinib).</ListItem><ListItem>Temozolomide.</ListItem><ListItem>Vascular endothelial growth factor pathway inhibitors.</ListItem><ListItem>Mammalian target of rapamycin inhibitors (e.g., everolimus).</ListItem></ItemizedList><Para id="_239">Nearly all of the evidence of activity derives from case series.[<LOERef href="CDR0000587991">Level of evidence 3iiiDiv</LOERef>]  However, there are ongoing placebo-controlled randomized trials of everolimus <Reference refidx="19"/> and sunitinib <Reference refidx="20"/> that have been reported in abstract form showing an increase in progression-free survival in each case.[<LOERef href="CDR0000335124">Level of evidence 1iDiii</LOERef>]</Para><Para id="_240">Favorable responses have been reported in patients with advanced progressive pancreatic NETs after treatment with several radiolabeled somatostatin analogs in which the analogs octreotide, octreotate, lanreotide, or edotreotide are stably attached to the radionuclides 111Indium, 90Ytrium, or 177Lutrium.<Reference refidx="21"/><Reference refidx="22"/> <Reference refidx="23"/>     The relative efficacy of these various compounds is unknown.  Study designs have been limited to case series with tumor response, biochemical response, or symptom control as the measure of efficacy.[<LOERef href="CDR0000587991">Level of evidence 3iiiDiv</LOERef>]</Para><Para id="_241">As noted in each of the clinical situations, there is a paucity or absence of high-level evidence, and a need for randomized controlled trials.<Reference refidx="5"/></Para></SummarySection><SummarySection id="_TrialSearch_162_sid_4"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_162_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=43353&amp;tt=1&amp;format=2&amp;cn=1">islet cell carcinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_162_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation><Citation idx="2" PMID="18335273">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct.</Citation><Citation idx="3" PMID="16924083">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006.</Citation><Citation idx="4" PMID="12039924">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002.</Citation><Citation idx="5" PMID="21263089">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011.</Citation><Citation idx="6" PMID="12735141">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003.</Citation><Citation idx="7" PMID="16134179">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.</Citation><Citation idx="8" PMID="15471830">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004.</Citation><Citation idx="9" PMID="18525307">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.</Citation><Citation idx="10" PMID="18618495">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.</Citation><Citation idx="11" PMID="11376399">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.</Citation><Citation idx="12" PMID="19370671">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev  (2): CD007060, 2009.</Citation><Citation idx="13" PMID="19160322">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev  (1): CD007118, 2009.</Citation><Citation idx="14" PMID="8625251">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996.</Citation><Citation idx="15" PMID="1310159" MedlineID="92123309">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992.</Citation><Citation idx="16" PMID="15570077">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004.</Citation><Citation idx="17" PMID="19118063">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009.</Citation><Citation idx="18" PMID="19933912">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.</Citation><Citation idx="19">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol  21 (Suppl 8): A-LBA9, viii4-5, 2010.</Citation><Citation idx="20">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida.  A-127, 2010.</Citation><Citation idx="21" PMID="16183530">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.</Citation><Citation idx="22" PMID="18445841">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.</Citation><Citation idx="23" PMID="20194865">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_29"><SectMetaData><SpecificDiagnosis ref="CDR0000038718">gastrinoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Gastrinoma</Title><Para id="_30">The approach to treatment often depends on the results of preoperative
localization studies and findings at exploratory laparotomy.  At exploration,
85% of these tumors are found in the gastrinoma triangle with 40% on the
surface of the pancreas and 40% outside of the pancreas.  Only 15% are found
within the substance of the pancreas.  Percutaneous transhepatic venous
sampling may occasionally provide accurate localization of single sporadic
gastrinomas.   Resection (enucleation of individual tumors, if technically feasible), and even excision of liver metastases, is associated with long-term cure or disease control.<Reference refidx="1"/>
</Para><Para id="_31"><Strong>Standard treatment options:
</Strong></Para><OrderedList id="_82" Style="Arabic"><ListItem> Single lesion in head of the pancreas:<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><ItemizedList id="_33" Style="bullet"><ListItem>Enucleation.
</ListItem>
<ListItem>Parietal cell vagotomy and cimetidine.
</ListItem>
<ListItem>Total gastrectomy (rarely used with the advent of current therapies).
</ListItem>
</ItemizedList>
</ListItem><ListItem>Single or multiple lesions in the duodenum:<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>
<ItemizedList id="_35" Style="bullet"><ListItem>Pancreatoduodenectomy.
</ListItem>
</ItemizedList></ListItem><ListItem>Single lesion in body/tail of the pancreas:<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>
<ItemizedList id="_37" Style="bullet"><ListItem>Resection of body/tail.
</ListItem>
</ItemizedList></ListItem><ListItem>Multiple lesions in pancreas:<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/>
<ItemizedList id="_39" Style="bullet"><ListItem>Resection of body/tail and, if residual disease is present,
</ListItem>
<ListItem>Parietal cell vagotomy and cimetidine, or
</ListItem>
<ListItem>Total gastrectomy (rarely used with the advent of current therapies).
</ListItem>
</ItemizedList></ListItem><ListItem> No tumor found:
<ItemizedList id="_41" Style="bullet"><ListItem>Parietal cell vagotomy and cimetidine.
</ListItem>
<ListItem>Total gastrectomy (rarely used with the advent of current therapies).
</ListItem>
</ItemizedList></ListItem><ListItem>Liver metastases:<Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/><Reference refidx="13"/><ItemizedList id="_43" Style="bullet"><ListItem>Liver resection where possible.</ListItem><ListItem>Radiofrequency ablation or cryosurgical ablation.</ListItem><ListItem>Chemoembolization of liver. 
</ListItem>
</ItemizedList></ListItem><ListItem>Metastatic disease or disease refractory to surgery and cimetidine:<Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/><Reference refidx="22"/> <Reference refidx="23"/><ItemizedList id="_45" Style="bullet"><ListItem>Chemotherapy
</ListItem>
<ListItem>Somatostatin analogue therapy.
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_47">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
bulk or hormone-release syndromes may benefit from procedures that reduce
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
embolization or with chemoembolization).  Such treatment may also be combined
with systemic chemotherapy in selected patients. Treatment with proton pump inhibitors or H2 blocking agents may  aid in control of peptic symptoms.
</Para><Para id="_181">In the era of proton pump inhibitors and H2 blocking agents, the potentially lethal hyperacidity and hypersecretory states induced by excessive gastrin production can usually be controlled. In a series of 212 patients with Zollinger-Ellison syndrome (ZES), no patients died of causes related to acid hypersecretion. Of those patients, only 2.3% had been subjected to total gastrectomy, and  the cohort upon which the report was based had a long median follow-up period of 13.8 years. Although 32% of the patients died during the course of the study, only 50% of the 67 deaths were attributable to ZES-related causes. Those causes were mainly liver metastases with progressive anorexia and cachexia (67%) or secondary endocrine tumors consequent to MEN-1 syndrome. The development of bone or liver metastases (especially diffuse liver disease) or of ectopic Cushing syndrome during the study period predicted for decreased survival times.<Reference refidx="24"/></Para><SummarySection id="_TrialSearch_29_sid_5"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_29_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38718&amp;tt=1&amp;format=2&amp;cn=1">gastrinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_29_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="16926567">Norton JA, Fraker DL, Alexander HR, et al.: Surgery increases survival in patients with gastrinoma. Ann Surg 244 (3): 410-9, 2006.</Citation><Citation idx="2" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation><Citation idx="3" PMID="18335273">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct.</Citation><Citation idx="4" PMID="16924083">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006.</Citation><Citation idx="5" PMID="12039924">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002.</Citation><Citation idx="6" PMID="12735141">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003.</Citation><Citation idx="7" PMID="16134179">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.</Citation><Citation idx="8" PMID="15471830">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004.</Citation><Citation idx="9" PMID="18525307">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.</Citation><Citation idx="10" PMID="18618495">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.</Citation><Citation idx="11" PMID="11376399">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.</Citation><Citation idx="12" PMID="19370671">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev  (2): CD007060, 2009.</Citation><Citation idx="13" PMID="19160322">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev  (1): CD007118, 2009.</Citation><Citation idx="14" PMID="8625251">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996.</Citation><Citation idx="15" PMID="1310159" MedlineID="92123309">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992.</Citation><Citation idx="16" PMID="15570077">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004.</Citation><Citation idx="17" PMID="19118063">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009.</Citation><Citation idx="18" PMID="19933912">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.</Citation><Citation idx="19">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol  21 (Suppl 8): A-LBA9, viii4-5, 2010.</Citation><Citation idx="20">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida.  A-127, 2010.</Citation><Citation idx="21" PMID="16183530">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.</Citation><Citation idx="22" PMID="18445841">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.</Citation><Citation idx="23" PMID="20194865">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.</Citation><Citation idx="24" PMID="2886085" MedlineID="87268968">Kvols LK, Buck M, Moertel CG, et al.: Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107 (2): 162-8, 1987.</Citation></ReferenceSection></SummarySection><SummarySection id="_48"><SectMetaData><SpecificDiagnosis ref="CDR0000038792">insulinoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Insulinoma</Title><Para id="_182">Curative surgical excision, by open laparotomy or laparoscopy, is the treatment of choice when possible.  The open surgical approach is used if the tumor is suspected to be malignant, since en bloc lymphadenectomy is performed for malignant tumors without distant metastases.  Intraoperative ultrasound aids the localization of tumor extent and the relationship to other anatomic structures.<Reference refidx="1"/> </Para><Para id="_49"><Strong>Standard treatment options:</Strong>
</Para><OrderedList id="_83" Style="Arabic" Compact="No"><ListItem>Single, small lesion in head or tail of pancreas:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>
<ItemizedList id="_51" Style="bullet"><ListItem>Enucleation, if feasible.
</ListItem>
</ItemizedList></ListItem><ListItem>	Large lesion in the head of the pancreas that is not amenable to enucleation:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_183" Style="bullet">
     <ListItem>Pancreaticoduodenectomy. </ListItem></ItemizedList></ListItem><ListItem>Single, large lesion in body/tail:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_242" Style="bullet">
     <ListItem>Distal pancreatectomy.</ListItem></ItemizedList>
</ListItem><ListItem>Multiple lesions:  occur in 10%, often in association with  multiple endocrine neoplasia syndrome type 1 (MEN-1):<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_184" Style="bullet">
     <ListItem>Distal pancreatectomy with enucleation of tumors in the head of the pancreas.</ListItem></ItemizedList></ListItem><ListItem>Metastatic lesions: lymph nodes or distant sites:<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>
<ItemizedList id="_57" Style="bullet"><ListItem>Resect when possible.</ListItem>
<ListItem>Consider radiofrequency or cryosurgical ablation, if not resectable.</ListItem></ItemizedList></ListItem><ListItem>Unresectable:<Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/> <Reference refidx="22"/><ItemizedList id="_59" Style="bullet"><ListItem>Combination chemotherapy.
</ListItem>
<ListItem>Pharmacologic palliation:  diazoxide 300 to 500 mg/day.
</ListItem>
<ListItem>Somatostatin analogue therapy.
</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_61">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
bulk or hormone-release syndromes may benefit from procedures that reduce
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
embolization or with chemoembolization).<Reference refidx="6"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>  Such treatment may also be combined
with systemic chemotherapy in selected patients.
</Para><SummarySection id="_TrialSearch_48_sid_6"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_48_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38792&amp;tt=1&amp;format=2&amp;cn=1">insulinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_48_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation><Citation idx="2" PMID="18335273">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct.</Citation><Citation idx="3" PMID="16924083">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006.</Citation><Citation idx="4" PMID="12039924">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002.</Citation><Citation idx="5" PMID="12735141">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003.</Citation><Citation idx="6" PMID="16134179">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.</Citation><Citation idx="7" PMID="15471830">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004.</Citation><Citation idx="8" PMID="18525307">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.</Citation><Citation idx="9" PMID="18618495">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.</Citation><Citation idx="10" PMID="11376399">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.</Citation><Citation idx="11" PMID="19370671">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev  (2): CD007060, 2009.</Citation><Citation idx="12" PMID="19160322">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev  (1): CD007118, 2009.</Citation><Citation idx="13" PMID="8625251">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996.</Citation><Citation idx="14" PMID="1310159" MedlineID="92123309">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992.</Citation><Citation idx="15" PMID="15570077">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004.</Citation><Citation idx="16" PMID="19118063">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009.</Citation><Citation idx="17" PMID="19933912">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.</Citation><Citation idx="18">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol  21 (Suppl 8): A-LBA9, viii4-5, 2010.</Citation><Citation idx="19">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida.  A-127, 2010.</Citation><Citation idx="20" PMID="16183530">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.</Citation><Citation idx="21" PMID="18445841">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.</Citation><Citation idx="22" PMID="20194865">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_88"><SectMetaData><SpecificDiagnosis ref="CDR0000038989">glucagonoma</SpecificDiagnosis><SectionType>Treatment options by stage</SectionType></SectMetaData><Title>Glucagonoma</Title><Para id="_185">As with the other pancreatic neuroendocrine tumors, the mainstay of therapy is surgical resection, and extended survival is possible even when the disease is metastatic.  Resection of metastases is also a consideration when feasible.<Reference refidx="1"/></Para><Para id="_89"><Strong>Standard treatment options:</Strong></Para><OrderedList id="_84" Style="Arabic" Compact="No"><ListItem>Single, small lesion in head or tail of pancreas:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_66" Style="bullet"><ListItem>Enucleation, if feasible.
</ListItem>
</ItemizedList></ListItem><ListItem>Large lesion in the head of the pancreas that is not amenable to enucleation:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_186" Style="bullet">
     <ListItem>Pancreaticoduodenectomy.</ListItem></ItemizedList></ListItem><ListItem>Single, large lesion in body/tail:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><ItemizedList id="_68" Style="bullet"><ListItem>Distal pancreatectomy.
</ListItem>
</ItemizedList></ListItem><ListItem>Multiple lesions:<Reference refidx="1"/><Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/>
<ItemizedList id="_70" Style="bullet"><ListItem>Enucleation, if feasible. </ListItem><ListItem>Resect body and tail otherwise.
</ListItem>
</ItemizedList></ListItem><ListItem>Metastatic disease: lymph nodes or distant sites:<Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>
<ItemizedList id="_72" Style="bullet"><ListItem>Resect when possible.</ListItem>
<ListItem>  Consider radiofrequency or cryosurgical ablation, if not resectable.
 </ListItem></ItemizedList></ListItem><ListItem> Unresectable disease:<Reference refidx="13"/><Reference refidx="14"/><Reference refidx="15"/><Reference refidx="16"/><Reference refidx="17"/><Reference refidx="18"/><Reference refidx="19"/><Reference refidx="20"/><Reference refidx="21"/> <Reference refidx="22"/>
<ItemizedList id="_74" Style="bullet"><ListItem>Combination chemotherapy.
</ListItem>
<ListItem>Somatostatin analogue therapy. 
 Necrotizing erythema of glucagonoma may be relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week.</ListItem>
</ItemizedList></ListItem></OrderedList><Para id="_90">Patients with hepatic-dominant disease and substantial symptoms caused by tumor
bulk or hormone-release syndromes may benefit from procedures that reduce
hepatic arterial blood flow to metastases (hepatic arterial occlusion with
embolization or with chemoembolization).<Reference refidx="6"/><Reference refidx="8"/><Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/><Reference refidx="12"/>  Such treatment may also be combined
with systemic chemotherapy in selected patients.</Para><SummarySection id="_TrialSearch_88_sid_7"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_88_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38989&amp;tt=1&amp;format=2&amp;cn=1">glucagonoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_88_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation><Citation idx="2" PMID="18335273">Phan GQ, Yeo CJ, Hruban RH, et al.: Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: Review of 125 patients. J Gastrointest Surg 2 (5): 473-82, 1998 Sep-Oct.</Citation><Citation idx="3" PMID="16924083">Kazanjian KK, Reber HA, Hines OJ: Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 141 (8): 765-9; discussion 769-70, 2006.</Citation><Citation idx="4" PMID="12039924">Hochwald SN, Zee S, Conlon KC, et al.: Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 20 (11): 2633-42, 2002.</Citation><Citation idx="5" PMID="12735141">Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 12 (1): 231-42, 2003.</Citation><Citation idx="6" PMID="16134179">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.</Citation><Citation idx="7" PMID="15471830">Nguyen C, Faraggi M, Giraudet AL, et al.: Long-term efficacy of radionuclide therapy in patients with disseminated neuroendocrine tumors uncontrolled by conventional therapy. J Nucl Med 45 (10): 1660-8, 2004.</Citation><Citation idx="8" PMID="18525307">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.</Citation><Citation idx="9" PMID="18618495">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.</Citation><Citation idx="10" PMID="11376399">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.</Citation><Citation idx="11" PMID="19370671">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev  (2): CD007060, 2009.</Citation><Citation idx="12" PMID="19160322">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev  (1): CD007118, 2009.</Citation><Citation idx="13" PMID="8625251">di Bartolomeo M, Bajetta E, Buzzoni R, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77 (2): 402-8, 1996.</Citation><Citation idx="14" PMID="1310159" MedlineID="92123309">Moertel CG, Lefkopoulo M, Lipsitz S, et al.: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326 (8): 519-23, 1992.</Citation><Citation idx="15" PMID="15570077">Kouvaraki MA, Ajani JA, Hoff P, et al.: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22 (23): 4762-71, 2004.</Citation><Citation idx="16" PMID="19118063">Kulke MH, Hornick JL, Frauenhoffer C, et al.: O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15 (1): 338-45, 2009.</Citation><Citation idx="17" PMID="19933912">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.</Citation><Citation idx="18">Yao JC, Shah MH, Ito T, et al.: A randomized, double-blind, placebo-controlled multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). [Abstract] Ann Oncol  21 (Suppl 8): A-LBA9, viii4-5, 2010.</Citation><Citation idx="19">Raymond E, Niccoli-Sire P, Bang Y: Updated results of the phase III trial of sunitinib (SU) versus placebo (PBO) for treatment of advanced pancreatic neuroendocrine tumors (NET). [Abstract] American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, 22–24 January 2010, Orlando, Florida.  A-127, 2010.</Citation><Citation idx="20" PMID="16183530">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.</Citation><Citation idx="21" PMID="18445841">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.</Citation><Citation idx="22" PMID="20194865">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_62"><SectMetaData><SpecificDiagnosis ref="CDR0000550688">islet cell tumor</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Miscellaneous Islet Cell Tumors</Title><SummarySection id="_187"><Title>VIPoma</Title><Para id="_188">Immediate fluid resuscitation is often necessary to correct the electrolyte and fluid problems that occur as a result of the watery diarrhea, hypokalemia, and achlorhydria that patients experience.  Somatostatin analogs are also used to ameliorate the large fluid and electrolyte losses.  Once patients are stabilized, excision of the primary tumor and regional nodes is the first line of therapy for clinically localized disease.  In the case of locally advanced or metastatic disease, where curative resection is not possible, debulking and removal of gross disease, including metastases, should be considered to alleviate the characteristic manifestations of VIP overproduction.<Reference refidx="1"/>  (Refer to the <SummaryRef href="CDR0000062794#_162" url="/types/pancreatic/hp/pnet-treatment-pdq">Treatment Option Overview</SummaryRef> section of this summary for information about the remaining principles of therapy.)</Para></SummarySection><SummarySection id="_189"><Title>Somatostatinoma</Title><Para id="_190">Complete excision is the therapy of choice, if technically possible.  However, metastases often preclude curative resection, and palliative debulking can be considered to relieve symptoms.<Reference refidx="1"/> (Refer to the <SummaryRef href="CDR0000062794#_162" url="/types/pancreatic/hp/pnet-treatment-pdq">Treatment Option Overview</SummaryRef> section of this summary for information about the remaining principles of therapy.)</Para></SummarySection><SummarySection id="_191"><Title>Other Pancreatic Neuroendocrine Tumors </Title><Para id="_192">For these very rare tumors, complete surgical excision is the only curative option when technically possible, and debulking or somatostatin analogs are used for palliation of symptoms if the tumor is functional. (Refer to the <SummaryRef href="CDR0000062794#_162" url="/types/pancreatic/hp/pnet-treatment-pdq">Treatment Option Overview</SummaryRef> section of this summary for information about the remaining principles of therapy.) </Para></SummarySection><SummarySection id="_TrialSearch_62_sid_8"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_62_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=550688&amp;tt=1&amp;format=2&amp;cn=1">islet cell tumor</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_62_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="19281699">Davies K, Conlon KC: Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 11 (2): 119-27, 2009.</Citation></ReferenceSection></SummarySection><SummarySection id="_78"><SectMetaData><SpecificDiagnosis ref="CDR0000038794">recurrent islet cell carcinoma</SpecificDiagnosis><SectionType>Treatment by stage--legacy</SectionType></SectMetaData><Title>Recurrent and Progressive Pancreatic Neuroendocrine Tumors</Title><Para id="_193">There is no established therapy for pancreatic neuroendocrine tumors that recur or progress after prior therapy.<Reference refidx="1"/> Deciding on further treatment depends on many factors,  including:</Para><ItemizedList id="_194" Style="bullet"><ListItem>The specific
cancer.</ListItem><ListItem> Prior treatment.</ListItem><ListItem>Site of recurrence.</ListItem><ListItem>Individual patient
considerations.</ListItem></ItemizedList><Para id="_195">Attempts at
re-resection of local tumors that have recurred or metastatic lesions may offer palliation,  when technically feasible.  Intra-arterial chemotherapy 
 is a consideration for patients with liver metastases.  Patients with hepatic-dominant disease and
substantial symptoms caused by tumor bulk or hormone-release syndromes may
benefit from continuous-infusion intra-arterial chemotherapy or procedures that
reduce hepatic arterial blood flow to metastases (hepatic arterial occlusion
with embolization or with chemoembolization).<Reference refidx="2"/><Reference refidx="3"/><Reference refidx="4"/><Reference refidx="5"/><Reference refidx="6"/><Reference refidx="7"/>  Such treatment may also be
combined with systemic chemotherapy.  A variety of systemic agents have shown biologic or palliative activity,<Reference refidx="1"/><Reference refidx="8"/> including:</Para><ItemizedList id="_196" Style="bullet">
     <ListItem>Somatostatin analogs.</ListItem><ListItem>Radiolabeled somatostatin analogs.<Reference refidx="9"/><Reference refidx="10"/><Reference refidx="11"/></ListItem><ListItem>Tyrosine kinase inhibitors (e.g., sunitinib).</ListItem><ListItem>Temozolomide.</ListItem><ListItem>Vascular endothelial growth factor pathway inhibitors.</ListItem><ListItem>Mammalian target of rapamycin inhibitors (e.g., everolimus).</ListItem></ItemizedList><SummarySection id="_TrialSearch_78_sid_9"><Title>Current Clinical Trials</Title><Para id="_TrialSearch_78_10">Check for U.S. clinical trials from NCI's list of cancer clinical trials that are now accepting patients with 
<ExternalRef xref="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=38794&amp;tt=1&amp;format=2&amp;cn=1">recurrent islet cell carcinoma</ExternalRef>. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.</Para><Para id="_TrialSearch_78_18">General information about clinical trials is also available from the <ExternalRef xref="http://www.cancer.gov/clinicaltrials">NCI Web site</ExternalRef>.</Para></SummarySection><ReferenceSection><Citation idx="1" PMID="21263089">Kulke MH, Siu LL, Tepper JE, et al.: Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29 (7): 934-43, 2011.</Citation><Citation idx="2" PMID="16134179">Gupta S, Johnson MM, Murthy R, et al.: Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104 (8): 1590-602, 2005.</Citation><Citation idx="3" PMID="18525307">Kennedy AS, Dezarn WA, McNeillie P, et al.: Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31 (3): 271-9, 2008.</Citation><Citation idx="4" PMID="18618495">King J, Quinn R, Glenn DM, et al.: Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 113 (5): 921-9, 2008.</Citation><Citation idx="5" PMID="11376399">Siperstein AE, Berber E: Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 25 (6): 693-6, 2001.</Citation><Citation idx="6" PMID="19370671">Gurusamy KS, Ramamoorthy R, Sharma D, et al.: Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev  (2): CD007060, 2009.</Citation><Citation idx="7" PMID="19160322">Gurusamy KS, Pamecha V, Sharma D, et al.: Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours. Cochrane Database Syst Rev  (1): CD007118, 2009.</Citation><Citation idx="8" PMID="19933912">Yao JC, Lombard-Bohas C, Baudin E, et al.: Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 28 (1): 69-76, 2010.</Citation><Citation idx="9" PMID="16183530">Teunissen JJ, Kwekkeboom DJ, de Jong M, et al.: Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 19 (4): 595-616, 2005.</Citation><Citation idx="10" PMID="18445841">Kwekkeboom DJ, de Herder WW, Kam BL, et al.: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26 (13): 2124-30, 2008.</Citation><Citation idx="11" PMID="20194865">Bushnell DL Jr, O'Dorisio TM, O'Dorisio MS, et al.: 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 28 (10): 1652-9, 2010.</Citation></ReferenceSection></SummarySection><SummarySection id="_91"><SectMetaData><SectionType>Changes to summary</SectionType></SectMetaData><Title>Changes to This Summary (04/30/2015)</Title><Para id="_92">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available.  This section describes the latest changes made to this summary as of the date above.</Para><Para id="_268"><Strong><SummaryRef href="CDR0000062794#_1" url="/types/pancreatic/hp/pnet-treatment-pdq">General Information About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)</SummaryRef></Strong></Para><Para id="_269">Editorial changes were made to this section.</Para><Para id="_disclaimerHP_3">This summary is written and maintained by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is
editorially independent of NCI.  The summary reflects an independent review of
the literature and does not represent a policy statement of NCI or NIH.  More
information about summary policies and the role of the PDQ Editorial Boards  in
maintaining the PDQ summaries can be found on the <SummaryRef href="CDR0000062794#_AboutThis_1" url="http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq">About This PDQ Summary</SummaryRef> and <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq">PDQ NCI's Comprehensive Cancer Database</ExternalRef> pages.
</Para></SummarySection><SummarySection id="_AboutThis_1"><Title>About This PDQ Summary</Title><SummarySection id="_AboutThis_2"><Title>Purpose of This Summary</Title><Para id="_AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</Para></SummarySection><SummarySection id="_AboutThis_4"><Title>Reviewers and Updates</Title><Para id="_AboutThis_5">This summary is reviewed regularly and updated as necessary by the <ExternalRef xref="http://www.cancer.gov/cancertopics/pdq/adult-treatment-board">PDQ Adult Treatment Editorial Board</ExternalRef>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</Para><Para id="_AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</Para><ItemizedList id="_AboutThis_6" Style="bullet"><ListItem>be discussed at a meeting,</ListItem><ListItem>be cited with text, or</ListItem><ListItem>replace or update an existing article that is already cited.</ListItem></ItemizedList><Para id="_AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</Para><Para>The lead reviewers for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment are:</Para><ItemizedList Style="bullet"><ListItem>Russell S. Berman, MD (New York University School of Medicine)</ListItem><ListItem>Franco M. Muggia, MD (New York University Medical Center)</ListItem></ItemizedList><Para id="_AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the Web site's <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</Para></SummarySection><SummarySection id="_AboutThis_10"><Title>Levels of Evidence</Title><Para id="_AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Adult Treatment Editorial Board uses a <SummaryRef href="CDR0000062796" url="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</SummaryRef> in developing its level-of-evidence designations.</Para></SummarySection><SummarySection id="_AboutThis_12"><Title>Permission to Use This Summary</Title><Para id="_AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</Para><Para id="_AboutThis_14">The preferred citation for this PDQ summary is:</Para><Para id="_AboutThis_15">National Cancer Institute: PDQ® Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment. Bethesda, MD: National Cancer Institute. Date last modified  &lt;MM/DD/YYYY&gt;. Available at: <ExternalRef xref="http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq">http://www.cancer.gov/types/pancreatic/hp/pnet-treatment-pdq</ExternalRef>.  Accessed &lt;MM/DD/YYYY&gt;.</Para><Para id="_AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <ExternalRef xref="http://visualsonline.cancer.gov/">Visuals Online</ExternalRef>, a collection of over 2,000 scientific images.

</Para></SummarySection><SummarySection id="_AboutThis_17"><Title>Disclaimer</Title><Para id="_AboutThis_18">Based on the strength of the available evidence, treatment options may be described as either “standard” or “under clinical evaluation.” These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <ExternalRef xref="http://www.cancer.gov/cancertopics/coping/financial-legal">Coping with Cancer: Financial, Insurance, and Legal Information</ExternalRef> page.</Para></SummarySection><SummarySection id="_AboutThis_20"><Title>Contact Us</Title><Para id="_AboutThis_21">More information about contacting us or receiving help with the Cancer.gov Web site can be found on our <ExternalRef xref="http://www.cancer.gov/help">Contact Us for Help</ExternalRef> page. Questions can also be submitted to Cancer.gov through the Web site’s <ExternalRef xref="http://www.cancer.gov/contact">Contact Form</ExternalRef>.
</Para></SummarySection></SummarySection> 

  <SummarySection id="_GetMore_3"><Title>Get More Information From NCI</Title><Para id="_GetMore_15"><Emphasis><Strong>Call 1-800-4-CANCER</Strong></Emphasis></Para><Para id="_GetMore_16">For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information Specialist is available to answer your questions.</Para><Para id="_GetMore_25"><Emphasis><Strong>Chat online 
</Strong></Emphasis></Para><Para id="_GetMore_26">The <ExternalRef xref="https://livehelp.cancer.gov/">NCI's LiveHelp®</ExternalRef> online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
</Para><Para id="_GetMore_27"><Emphasis><Strong>Write to us</Strong></Emphasis></Para><Para id="_GetMore_28">For more information from the NCI, please write to this address:</Para><ItemizedList id="_GetMore_29" Style="simple"><ListItem>NCI Public Inquiries Office</ListItem><ListItem>9609 Medical Center Dr. </ListItem><ListItem>Room 2E532 MSC 9760</ListItem><ListItem>Bethesda, MD 20892-9760</ListItem></ItemizedList><Para id="_GetMore_17"><Emphasis><Strong>Search the NCI Web site</Strong></Emphasis></Para><Para id="_GetMore_18">The <ExternalRef xref="http://cancer.gov">NCI Web site</ExternalRef> provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families.  For a quick search, use the search box in the upper right corner of each Web page. The results for a wide range of search terms will include a list of "Best Bets," editorially chosen Web pages that are most closely related to the search term entered.</Para><Para id="_GetMore_30">There are also many other places to get materials and information about cancer treatment and services.      Hospitals in your area may have information about  local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.</Para><Para id="_GetMore_19"><Emphasis><Strong>Find Publications</Strong></Emphasis></Para><Para id="_GetMore_20">The NCI has booklets and other materials for patients, health professionals, and the public.  These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials.  Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities.  NCI materials on these and other topics may be ordered online or printed directly from the <ExternalRef xref="https://pubs.cancer.gov/ncipl">NCI Publications Locator</ExternalRef>. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</Para></SummarySection><DateLastModified>2015-04-30</DateLastModified></Summary>
